{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:25:07Z","timestamp":1790601907158,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Artemether-lumefantrine (AL) is the first-line antimalarial drug for the treatment of uncomplicated malaria in Tanzania. The World Health Organization (WHO) recommends regular efficacy monitoring of antimalarial drugs to inform case management policy decisions. This study assessed the safety and efficacy of AL for treating uncomplicated Plasmodium falciparum malaria in Tanzania in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children aged 6 months to 10 years with uncomplicated P falciparum malaria were recruited from 4 sentinel sites and treated with the standard 6-dose, 3-day regimen for AL. Clinical and parasitological responses were monitored for 28 days using the WHO standard protocol. Genotyping based on msp1, msp2, and glurp was used to distinguish recrudescence from reinfection. Sanger sequencing was used to detect K13 mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three hundred fifty-two participants, 88 per site, were enrolled. Four withdrew and 55 experienced parasite recurrence. The polymerase chain reaction (PCR)\u2013corrected Kaplan-Meier efficacies were 89.9% in Pwani, 95.0% in Kigoma, 94.4% in Tanga, and 98.9% in Morogoro. No K13 mutations were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Artemether-lumefantrine remains highly efficacious in 3 regions of Tanzania, but the PCR-corrected efficacy in Pwani fell below the WHO-defined 90% threshold at which policy change is recommended. Implementing strategies to diversify artemisinin-based combination therapies to ensure effective case management in Tanzania is critical.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae425","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:28:46Z","timestamp":1724686126000},"page":"251-259","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Artemether-Lumefantrine Against Uncomplicated Falciparum Malaria Infection in Tanzania, 2022: A Single-Arm Clinical Trial"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-0488","authenticated-orcid":false,"given":"Jessica E","family":"Laury","sequence":"first","affiliation":[{"name":"Global Health Fellowship Program, Public Health Institute , Oakland, California"},{"name":"Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases"},{"name":"US President's Malaria Initiative, Centers for Disease Control and Prevention , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefas","family":"Mugittu","sequence":"additional","affiliation":[{"name":"Shinda Malaria, Ifakara Health Institute , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora C","family":"Kajeguka","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Kilimanjaro Christian Medical University College , Moshi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Kamugisha","sequence":"additional","affiliation":[{"name":"Catholic University of Health and Allied Sciences, Bugando Medical Centre , Mwanza"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deus S","family":"Ishengoma","sequence":"additional","affiliation":[{"name":"Headquarters, National Institute for Medical Research , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine I","family":"Mandara","sequence":"additional","affiliation":[{"name":"Headquarters, National Institute for Medical Research , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Ngasala","sequence":"additional","affiliation":[{"name":"Department of Parasitology and Medical Entomology, Muhimbili University of Health and Allied Sciences , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy G","family":"Chiduo","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research, Tanga Research Center , Tanga"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhidin K","family":"Mahende","sequence":"additional","affiliation":[{"name":"Shinda Malaria, Ifakara Health Institute , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovin","family":"Kitau","sequence":"additional","affiliation":[{"name":"Communicable and Non-communicable Disease Cluster, World Health Organization , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maimuna M","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Catholic University of Health and Allied Sciences, Bugando Medical Centre , Mwanza"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixbert I","family":"Mkumbaye","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Kilimanjaro Christian Medical University College , Moshi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-4729","authenticated-orcid":false,"given":"Filbert","family":"Francis","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research, Tanga Research Center , Tanga"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Chacky","sequence":"additional","affiliation":[{"name":"National Malaria Control Program , Mtumba, Dodoma ,","place":["Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Warsame","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Gothenburg University , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Serbantez","sequence":"additional","affiliation":[{"name":"US President's Malaria Initiative, US Agency for International Development"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonge","family":"Kitojo","sequence":"additional","affiliation":[{"name":"US President's Malaria Initiative, US Agency for International Development"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik J","family":"Reaves","sequence":"additional","affiliation":[{"name":"US President's Malaria Initiative, Center for Disease Control and Prevention , Dar Es Salaam ,","place":["Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunstan R","family":"Bishanga","sequence":"additional","affiliation":[{"name":"Shinda Malaria, Ifakara Health Institute , Dar es Salaam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Bajic","sequence":"additional","affiliation":[{"name":"Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases"},{"name":"US President's Malaria Initiative, Centers for Disease Control and Prevention , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilali I","family":"Kabula","sequence":"additional","affiliation":[{"name":"US Agency for International Development\/Okoa Maisha Dhibiti Malaria, RTI International , Dar Es Salaam"},{"name":"Amani Centre, National Institute for Medical Research , Muheza, Tanga"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florida","family":"Muro","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Kilimanjaro Christian Medical University College , Moshi"},{"name":"Community Health Department, Kilimanjaro Christian Medical Centre , Moshi ,","place":["Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald A","family":"Kavishe","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Kilimanjaro Christian Medical University College , Moshi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"2025020417140846900_jiae425-B1","author":"Ministry of Health Tanzania Mainland, Ministry of Health Zanzibar, National Bureau of Statistics, Office of the Chief Government Statistician, and ICF"},{"key":"2025020417140846900_jiae425-B2","author":"World Health Organization (WHO)"},{"key":"2025020417140846900_jiae425-B3","author":"US President\u2019s Malaria Initiative"},{"key":"2025020417140846900_jiae425-B4","author":"World Health Organization"},{"key":"2025020417140846900_jiae425-B5","author":"National Malaria Control Program Tanzania"},{"key":"2025020417140846900_jiae425-B6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/1475-2875-13-376","article-title":"Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in north-eastern Tanzania","volume":"13","author":"Shayo","year":"2014","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","article-title":"Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania","volume":"18","author":"Ishengoma","year":"2019","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12936-018-2409-z","article-title":"High efficacy of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma districts, Tanzania","volume":"17","author":"Mandara","year":"2018","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B9","doi-asserted-by":"publisher","author":"Ishengoma","DOI":"10.1101\/2024.01.31.24301954"},{"key":"2025020417140846900_jiae425-B10","author":"World Health Organization (WHO)"},{"key":"2025020417140846900_jiae425-B11","author":"Worldwide Antimalarial Resistance Network"},{"key":"2025020417140846900_jiae425-B12","author":"World Health Organization"},{"key":"2025020417140846900_jiae425-B13","author":"World Health Organization"},{"key":"2025020417140846900_jiae425-B14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetic and pharmacodynamics of artemether-lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"2025020417140846900_jiae425-B15","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","article-title":"Understanding the pharmacokinetics of Coartem","volume":"8 Suppl 1","author":"Djimde","year":"2009","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","article-title":"Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018","volume":"20","author":"Gansan\u00e9","year":"2021","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B17","doi-asserted-by":"crossref","first-page":"e01949-20","DOI":"10.1128\/AAC.01949-20","article-title":"Continued low efficacy of artemether-lumefantrine in Angola in 2019","volume":"65","author":"Dimbu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020417140846900_jiae425-B18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","article-title":"Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance","volume":"105","author":"Moriarty","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2025020417140846900_jiae425-B19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12936-019-2740-z","article-title":"High cure rates and tolerability of artesunate\u2013amodiaquine and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania","volume":"18","author":"Mandara","year":"2019","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3201\/eid2608.191547","article-title":"Increased sensitivity of Plasmodium falciparum to artesunate\/amodiaquine despite 14 years as first-line malaria treatment, Zanzibar","volume":"26","author":"Msellem","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025020417140846900_jiae425-B21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","article-title":"Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in mainland Tanzania","volume":"17","author":"Kakolwa","year":"2018","journal-title":"Malar J"},{"key":"2025020417140846900_jiae425-B22","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.0804628105","article-title":"Benefits of using multiple first-line therapies against malaria","volume":"105","author":"Boni","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025020417140846900_jiae425-B23","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","article-title":"Optimum population-level use of artemisinin combination therapies: a modelling study","volume":"3","author":"Nguyen","year":"2015","journal-title":"Lancet Glob Health"},{"key":"2025020417140846900_jiae425-B24","author":"World Health Organization"},{"key":"2025020417140846900_jiae425-B25","volume-title":"East Hanover","author":"Novartis Pharmaceuticals Corporation","year":"2009"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae425\/59151946\/jiae425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/251\/59151946\/jiae425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/251\/59151946\/jiae425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:23:25Z","timestamp":1738671805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/1\/251\/7742125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,26]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae425","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,8,26]]}}}